SMi Group Reports: Following the FDA’s release of a Biosimilar Action Plan, this year’s Biosimilars USA conference promises to explore the developments in biosimilar drug development As the world of biosimilars gains more tractionand promise, […]
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has discovered a new potential therapeutic target for clear cell renal cell carcinoma (RCC), the most common form of kidney cancer. The new target is a […]
Pfizer has initiated a phase 3 open-label, multi-centre and lead-in-study to evaluate the efficacy and safety of Spark Therapeutic’s investigational factor IX prophylaxis replacement gene therapy to treat haemophilia B. The commencement of the phase […]
GlaxoSmithKline (GSK) has gained the US Food and Drug Administration (FDA) priority review approval for its Krintafel (tafenoquine) to prevent malaria relapse caused by Plasmodium vivax (P. vivax). The indication covers s single-dose of the […]
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults. According to Janssen, single table regimens have the capacity to boost adherence […]